# Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

> **NCT02938793** · PHASE2 · TERMINATED · sponsor: **Prisma Health-Upstate** · enrollment: 92 (actual)

## Conditions studied

- Cancer
- Rare Disease

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT02938793
- **Lead sponsor:** Prisma Health-Upstate
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-01
- **Primary completion:** 2025-09-17
- **Final completion:** 2025-09-17
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** poor enrollment likely due to expanded availability of immunotherapy for patients
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938793, "Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02938793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*